Jolkinolide B from the roots of Euphorbia fischeriana Steud exhibits significant antitumor activities against several
tumor lines. Previous study has shown that
Jolkinolide B could induce apoptosis in human
leukemia cells. However, the exact mechanism and signaling pathway involved in
Jolkinolide B-induced apoptosis have not been fully elucidated. In the present study, we found that
Jolkinolide B reduced cell viability and induced apoptosis in dose- and time-dependent manner in human leukemic HL-60 and THP-1 cells. The induction of apoptosis was accompanied by the downregulation of JAK2/STAT3. Our results also suggest that expression of Bcl-2 and mitochondrial
cytochrome c was dosedependently reduced following
Jolkinolide B-treated THP-1 and HL-60 cells, whereas
Jolkinolide B up-regulated the expression of Bax and cytosolic
cytochrome c. Moreover, we observed that
Jolkinolide B treatment resulted in activation of
caspase-3, -8, and -9. JSI-124, a STAT-3 inhibitor, was able to block the negative effect of
Jolkinolide B on cell apoptosis. Taken together, our study for the first time suggests that
Jolkinolide B is able to enhance apoptosis of human leukemic HL-60 and THP-1 cells, at least in part, through downregulation of JAK2/STAT3 and bcl-2, and upregulation of Bax and cytosolic
cytochrome c. Moreover, the triggering of
caspase-3, -8, and -9 activation mediated apoptotic induction.